Bristol-myers Squibb Compnay

Chdi Foundation, Inc.

The Dupont Merck Pharmaceutical Company

Other

Dupont Pharmaceuticals Company

Irm LLC

Dupont Pharmaceuticals, Inc.

Hamilton

John Wityak

Celia Dominguez

Jagabandhu Das

Joel C Barrish

Arthur M P Doweyko

Michael Edward Prime

Christopher John Brown

Jonathan Bard

Daniel Clark-Frew

Peter David Johnson

Ping Chen

Derek J Norris

Sarah Hayes

Ramesh Padmanabha

Chunjian Liu

Steven B Kanner

Steven H Spergel

Samuel Coe

Thomas Martin Krülle

Stephen Martin Courtney

Joseph A Furch, Iii

Alex Kiselyov

Richard Waldron Marston

Shaker Ahmed Mousa

Christopher John Yarnold

William Frank Degrado

Sébastien René Gabriel Galan

Paul Richard Giles

Richard Eric Olson

Douglas G Batt

Xiaolin Li

Valentina Molteni

Prabhakar Kondaji Jadhav

Juliet Nabakka

Donald J Pinto

Leticia M Toledo-Sherman

Thomas Martin Krulle

Paula C De Aguiar Pena

Enrique Saez

Matthew Robert Mills

Dirk Winkler

Thais Motria Sielecki-Dzurdz

Duane Higgins

Andreas Scheel

Samantha Brown

William Henry Miller

Chu-Biao Xue

John J Duncia

Patricia C Weber

Gary Avonn Cain

Munir A Hussain

Gregory J Wells

Gregory James Pacofsky

Eugene Cruz Amparo

Anju Parthasarathy

Sharon Anne Jackson

Douglas Macdonald

Beth Anaclerio

Aleksandra Ewa Tobin

Elise Luciennen Paulette Gadouleau

Mimi Lifen Quan

Frederick Arthur Brookfield

William John Pitts

Joseph B Santella

Louis John Lombardo

Matthew Ernst Voss

Robert A Galemmo, Jr

James Russell Pruitt

David Brent Rawlins

Fang Liang

Francis Y F Lee

Gary L Schieven

David Archer Ellis

Petrus Fredericus Stouten

Arthur M Doweyko

Daryl Simon Walter

Joanne Marie Smallheer

Inaki Morao

Ian James Wigginton

Malcolm George Taylor

Joseph Basil Santella, Iii

Elise Lucienne Paulette Gadouleau

Joseph A Furch Iii

Mark Alden Hermsmeier

Derek Alexander Weddell

Francis Y Lee

Samantha Louise Jones Green

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

Probes for imaging huntingtin protein

Probes for imaging Huntingtin protein

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. 

Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use. 

Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use 

Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

Cyclic protein tyrosine kinase inhibitors

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Growing community of inventors

Carlsbad, CA, United States of America

John Wityak